BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
1.530
-0.030 (-1.92%)
At close: Apr 28, 2026, 4:00 PM EDT
1.510
-0.020 (-1.31%)
After-hours: Apr 28, 2026, 4:04 PM EDT
BeyondSpring Employees
BeyondSpring had 44 employees as of December 31, 2025. The number of employees increased by 4 or 10.00% compared to the previous year.
Employees
44
Change (1Y)
4
Growth (1Y)
10.00%
Revenue / Employee
n/a
Profits / Employee
-$22,864
Market Cap
62.91M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MindWalk Holdings | 102 |
| Seres Therapeutics | 66 |
| Cue Biopharma | 29 |
| iBio, Inc. | 20 |
| ImageneBio | 15 |
| Cingulate | 14 |
| Actuate Therapeutics | 12 |
| Annovis Bio | 7 |
BYSI News
- 6 days ago - BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs - GlobeNewsWire
- 4 weeks ago - BeyondSpring Files 2025 Annual Report on Form 10-K - GlobeNewsWire
- 2 months ago - BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference - GlobeNewsWire
- 4 months ago - BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - GlobeNewsWire
- 10 months ago - BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure - GlobeNewsWire
- 11 months ago - BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - GlobeNewsWire
- 1 year ago - BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewsWire